Story perspectives

Senators Clash Over Mifepristone Safety Amid Controversy

10/30/2025

38 7

Summary

Story summary

Live Action News argues Guttmacher Institute's report uses misleading tactics and claims 11% of women experience serious complications.
U.S. Sen. Steve Daines calls on U.S. President Donald Trump to review drug safety.
Planned Parenthood defends mifepristone, citing its 25-year safe use.
GOP senators worry recent Food and Drug Administration (FDA) approvals may undermine safety reviews.
Democratic attorneys general say the push for restrictions is politically motivated and lacks scientific backing.

1 of 1

Story summary

Live Action News argues Guttmacher Institute's report uses misleading tactics and claims 11% of women experience serious complications.
U.S. Sen. Steve Daines calls on U.S. President Donald Trump to review drug safety.
Planned Parenthood defends mifepristone, citing its 25-year safe use.
GOP senators worry recent Food and Drug Administration (FDA) approvals may undermine safety reviews.
Democratic attorneys general say the push for restrictions is politically motivated and lacks scientific backing.